Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Minimal residual disease in hairy cell leukemia patients assessed by clone-specific polymerase chain reaction.

Arons E, Margulies I, Sorbara L, Raffeld M, Stetler-Stevenson M, Pastan I, Kreitman RJ.

Clin Cancer Res. 2006 May 1;12(9):2804-11.

2.

Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation.

Böttcher S, Ritgen M, Pott C, Brüggemann M, Raff T, Stilgenbauer S, Döhner H, Dreger P, Kneba M.

Leukemia. 2004 Oct;18(10):1637-45.

PMID:
15343348
3.

MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR.

Pott C, Brüggemann M, Ritgen M, van der Velden VH, van Dongen JJ, Kneba M.

Methods Mol Biol. 2013;971:175-200. doi: 10.1007/978-1-62703-269-8_10.

PMID:
23296964
5.

Cladribine in hairy cell leukemia.

Belani R, Saven A.

Hematol Oncol Clin North Am. 2006 Oct;20(5):1109-23. Review.

PMID:
16990111
6.

Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia.

Donovan JW, Ladetto M, Zou G, Neuberg D, Poor C, Bowers D, Gribben JG.

Blood. 2000 Apr 15;95(8):2651-8.

7.

Minimal residual disease detection in hairy cell leukemia. Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene.

Sausville JE, Salloum RG, Sorbara L, Kingma DW, Raffeld M, Kreitman RJ, Imus PD, Venzon D, Stetler-Stevenson M.

Am J Clin Pathol. 2003 Feb;119(2):213-7.

PMID:
12579991
8.

[The detection of minimal residual disease in patients with chronic B-cell lymphatic leukemia using patient-specified polymerase chain reaction].

Sidorova IuV, Sorokina TV, Biderman BV, Nikulina EE, Kisilichina DG, Naumova EV, Pochtar' ME, Lugovskaia SA, Ivanova VL, Kovaleva LG, Ptushkin VV, Nikitin EA, Sudarikov AB.

Klin Lab Diagn. 2011 Dec;(12):22-4, 33-5. Russian.

PMID:
22416427
9.
10.

Improved assessment of minimal residual disease in B cell malignancies using fluorogenic consensus probes for real-time quantitative PCR.

Brüggemann M, Droese J, Bolz I, Lüth P, Pott C, von Neuhoff N, Scheuering U, Kneba M.

Leukemia. 2000 Aug;14(8):1419-25.

PMID:
10942238
11.

Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol.

Noy A, Verma R, Glenn M, Maslak P, Rahman ZU, Keenan JR, Weiss M, Filippa D, Zelenetz AD.

Blood. 2001 Apr 1;97(7):1929-36.

12.

Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia.

Verhagen OJ, Willemse MJ, Breunis WB, Wijkhuijs AJ, Jacobs DC, Joosten SA, van Wering ER, van Dongen JJ, van der Schoot CE.

Leukemia. 2000 Aug;14(8):1426-35.

PMID:
10942239
13.

Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes.

Pongers-Willemse MJ, Verhagen OJ, Tibbe GJ, Wijkhuijs AJ, de Haas V, Roovers E, van der Schoot CE, van Dongen JJ.

Leukemia. 1998 Dec;12(12):2006-14.

PMID:
9844931
14.

Stem cell transplantation in poor-risk chronic lymphocytic leukemia: assessment of post-transplant minimal residual disease using four- and six-color flow cytometry and allele-specific RQ-PCR.

Itälä M, Huhtinen AR, Juvonen V, Kairisto V, Pelliniemi TT, Penttilä TL, Rauhala A, Tienhaara A, Remes K.

Eur J Haematol. 2008 Aug;81(2):100-6. doi: 10.1111/j.1600-0609.2008.01082.x. Epub 2008 Apr 10.

PMID:
18410542
15.

Fluorescent polymerase chain reaction and capillary electrophoresis for IgH rearrangement and minimal residual disease evaluation in multiple myeloma.

Novella E, Giaretta I, Elice F, Madeo D, Piccin A, Castaman G, Rodeghiero F.

Haematologica. 2002 Nov;87(11):1157-64.

16.

Evaluation of residual disease in B-cell chronic lymphocytic leukemia patients in clinical and bone-marrow remission using CD5-CD19 markers and PCR study of gene rearrangements.

Vuillier F, Claisse JF, Vandenvelde C, Travade P, Magnac C, Chevret S, Desablens B, Binet JL, Dighiero G.

Leuk Lymphoma. 1992 Jun;7(3):195-204.

PMID:
1282428
17.
18.

Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation.

Farina L, Carniti C, Dodero A, Vendramin A, Raganato A, Spina F, Patriarca F, Narni F, Benedetti F, Olivieri A, Corradini P.

Haematologica. 2009 May;94(5):654-62. doi: 10.3324/haematol.2008.000273. Epub 2009 Apr 18.

19.

Peripheral blood 8 colour flow cytometry monitoring of hairy cell leukaemia allows detection of high-risk patients.

Garnache Ottou F, Chandesris MO, Lhermitte L, Callens C, Beldjord K, Garrido M, Bedin AS, Brouzes C, Villemant S, Rubio MT, Belanger C, Suarez F, Deau B, Lefrère F, Hermine O, Asnafi V, Varet B, Macintyre E.

Br J Haematol. 2014 Jul;166(1):50-9. doi: 10.1111/bjh.12839. Epub 2014 Mar 25.

PMID:
24661013

Supplemental Content

Support Center